In PDAC with KRAS mutation, inhibition of the MAPK pathway promotes tumor-protective autophagy, and combination therapy with both ERK and autophagy inhibitors has a synergistic effect, whereas either alone has a weaker effect [51]. This evidence concerns the gene KRAS and neoplasm.